The EMA has recommended label expansions for Inaqovi, Opdivo, and Venclyxto, broadening treatment options in AML, Hodgkin lymphoma, and CLL.

Study findings from the 2026 ASAM annual meeting showed that a multimodal program reduced opioid exposure in the emergency department and provided effective pain relief for substance use disorders.

Discover what digital marketing is and explore the top strategies, channels and best practices to grow your business online ...

If you want to earn interest on your cash without giving up easy access to your funds, a money market account (MMA) could be ...